This is a working overview of Metabolic modulator, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-22. Anything still debated is marked as such rather than presented as settled.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
=== Tobacco settlement === In 1988, Louisiana was one of 46 states to enter into a settlement with tobacco companies over smoking-related illnesses whereby each state could choose between annual payments or a smaller lump sum. Louisiana took the annual payments. As treasurer, Kennedy structured a deal to auction off part of the annual payments in exchange for a lump sum to hedge against the possibility that the tobacco companies could go bankrupt. At the time, Kennedy said, "If your rich uncle died and left you $4.4 billion, all of it in Philip Morris stock, what would you do? I would diversify." The proceeds from that sale were invested in trust funds earmarked for education, health care, and TOPS—a higher-education scholarship program. Kennedy opposed future sales of the debt. He argued that his early sale was only a hedge against a potential bankruptcy of the tobacco companies and should not be used as a short term fund to address immediate spending. In 2007, the Louisiana State Bond Commission voted to sell more of the settlement and Kennedy was the lone opposition vote. In 2015, Governor Jindal announced a plan to sell the remainder of the tobacco settlement in one lump sum of $751 million to help him address budget shortfalls rather than accepting the remaining $1.2 billion in annual payments. Kennedy opposed the plan, saying that taking the lump sum would be a "bonehead move" that the legislature would not support and adding: "I’ve talked to a number of legislators.
=== Music === The official military march of Russian Cossacks units is Cossacks in Berlin, composed by Dmitry Pokrass and Daniil Pokrass, with lyrics being made by Caesar Solodar. Solodar was present when Field Marshal Wilhelm Keitel signed the act of surrender to Allied forces. That same day, he left for Moscow and by the evening of 9 May, the song was written. The lyrics detail an interaction between a Cossack and a girl from Berlin. The S. Tvorun arrangement of the Zaporizhian March (known as the Cossack march) is one of the main marches of the Armed Forces of Ukraine, replacing Farewell of Slavianka in 1991 as the official sendoff music for army recruits. The Kuban Cossack Choir is a leading folkloric ensemble that reflects the dances and folklore of the Kuban Cossack. The second movement of Mily Balakirev's Second Symphony is marked "Scherzo alla Cosacca", which means "scherzo in the style of the Cossacks".
== Selected publications == Bounous, G; Molson, JH (2003). "The antioxidant system". Anticancer Research. 23 (2B): 1411–5. PMID 12820403. Kennedy, RS; Konok, GP; Bounous, G; Baruchel, S; Lee, TD (1995). "The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: A phase I-II clinical study". Anticancer Research. 15 (6B): 2643–9. PMID 8669840. Bounous, Gustavo; Somersall, Allan (April 1999). Breakthrough In Cell-Defense. GOLDENeight Publishing. ISBN 978-1-890412-86-9.
Counterfeit drugs are a serious problem. People can potentially ingest useless or dangerous drugs without their knowledge. Custom package seals, authentication labels, holograms, and security printing can be valued parts of an entire security system. They help verify that enclosed drugs are what the package says they are. Drug counterfeiters, however, often work with package counterfeiters, some of whom can be sophisticated. No packaging system is completely secure.
The most important drugs with a dipeptide (L-alanyl-L-proline) moiety are the "-pril" cardiovascular drugs, such as Alapril (lisinopril), Captoril (captopril), Novolac (imidapril) and Renitec (enalapril). The artificial sweetener Aspartame (N-L-α-Aspartyl-L-phenylalanine 1-methyl ester) is also a dipeptide. At the high end, there is the anticoagulant hirudin, MW ≈ 7000, which is composed of 65 amino acids. Apart from pharmaceuticals, peptides are also used for diagnostics and vaccines. The total production volume (excluding Aspartame) of chemically synthesized, pure peptides is about 1,500 kg (3,300 lb) and sales approach $500 million on the active pharmaceutical (API) level and $10 billion on the finished drug level, respectively. The bulk of the production of peptide drugs, which also include the first generation anti-AIDS drugs, the "...navirs", is outsourced to a few specialized contract manufacturers, such as Bachem, Switzerland; Chengu GT Biochem, China; Chinese Peptide Company, China; Lonza, Switzerland, and Polypeptide, Denmark. Proteins are "very high-molecular-weight" (MW > 100,000) organic compounds, consisting of amino acid sequences linked by peptide bonds. They are essential to the structure and function of all living cells and viruses and are among the most actively studied molecules in biochemistry. They can be made only by advanced biotechnological processes; primarily mammalian cell cultures. Monoclonal antibodies (mAb) prevail among human-made proteins. About a dozen of them are approved as pharmaceuticals.
Sources: en.wikipedia.org
=== Pharmacodynamics === Tapentadol is a synthetic opioid with a dual mechanism of action: it acts as a full agonist of the μ-opioid receptor (MOR) and as a norepinephrine reuptake inhibitor (NRI). This unique pharmacological profile allows it to treat both nociceptive and neuropathic pain, and it is theorised that the effects on norepinephrine are a substantial benefit for people taking it. Tapentadol does not affect serotonin, unlike tramadol, which prevents the reuptake of serotonin and norepinephrine, similarly to certain antidepressants known as serotonin–norepinephrine reuptake inhibitors (SNRIs), such as desvenlafaxine and duloxetine. Tapentadol exhibits high binding selectivity and affinity for MOR, which is the principal target of the endogenous neuropeptide β-endorphin. It has significantly lower affinity for the δ-opioid receptor (DOR), κ-opioid receptor (KOR) and M1 as an antimuscarinic effect. MOR binding sites are distributed throughout the human brain, with higher densities in regions such as the amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and select cortical areas. Opioids like tapentadol are believed to mediate analgesia primarily through MOR activation in the midbrain periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), thereby inhibiting ascending pain pathways. MOR activation in the intestine contributes to common opioid-related side effects such as constipation. As noted, tapentadol is structurally similar to tramadol, and both drugs utilize a dual mechanism involving the opioid and norepinephrine systems.
In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of people twelve years of age and older with stage IIB or IIC melanoma following complete resection. In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of renal cell carcinoma for people at intermediate-high or high risk of recurrence following nephrectomy. Approval was based on KEYNOTE-564, a multicenter, randomized (1:1), double-blind, placebo-controlled trial in 994 participants with intermediate-high or high risk of recurrence of RCC, or M1 no evidence of disease. In March 2022, the US FDA approved pembrolizumab for the treatment of advanced endometrial cancer. In January 2023, the US FDA approved pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung cancer. In October 2023, the US FDA approved pembrolizumab to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. In January 2024, the US FDA approved pembrolizumab, in combination with chemoradiotherapy for the treatment of people with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. In June 2024, the US FDA approved pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial carcinoma.
Light points and Combat pages are naturally restored by one unit per turn or by raising the Emotion level of that character, which will restore all Light points. Emotion level is a mechanic that raises whenever a character wins or loses a clash, or when their dice rolls its maximum or minimum value. The group will gain an emotional level-up after their average emotion level reaches a certain point. When the emotion level rises, the player must choose one Abnormality page to apply to a librarian. Abnormality pages come in two colors, green (Awakening) and red (Breakdown), each with its own beneficial effects and drawbacks. The emotion level can rise up to five times per battle, with a total of five Abnormality pages to be picked.
== Technology == Aroa Biosurgery develops medical devices using its proprietary ovine forestomach matrix (OFM) technology. OFM is a layer of decellularized extracellular matrix (ECM) biomaterial isolated from the propria submucosa of the rumen of sheep. OFM is used in tissue engineering and as a tissue scaffold for wound healing and surgical applications.
Sizeup: This is scouting and planning safe cuts for the felling direction, danger zones, and retreat paths, before starting the saw. The tree's location relative to other objects, support, and tension determines a safe fall, splits off, or if the saw will jam. Several factors to consider are tree lean and bend, wind direction, branch arrangement, snow load, obstacles and damaged, rotting tree parts, which might behave unexpectedly when cut. A tree may have to fall in its natural direction if it is too dangerous or impossible to fell in a desired direction. The aim is for the tree to fall safely for limbing and cross-cutting the log. The goal is to avoid having the tree fall on another tree or obstacle. Felling: After clearing the tree's base undergrowth for the retreat path and the felling direction; felling is properly done with three main cuts. To control the fall, the directional cut line should run 1/4 of the tree diameter to make a 45-degree wedge, which should be in the felling direction and horizontal. The top cut should be made first and then the bottom cut to form the directional line at the wedge point. A narrow or nonexistent hinge lessens felling direction control. From the opposite side of the wedge, the final felling cut is finished one-tenth of the tree diameter from the direction cut line. The felling cut is made horizontally and slightly 5 cm (2 in)) above the bottom cut. When the hinge is properly set, the felling cut will begin the fall in the desired direction. A sitback is when a tree moves back opposite the intended direction.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.